IHH HEALTHCARE BERHAD
Q0F.SI
IHH Healthcare - Core results within expectations
- 4Q15 headline earnings aided by exceptional items; core earnings fell 11% on interest, start-up costs
- Earnings growth to moderate slightly in FY16F
- Long term prospects reflected in share price on premium valuation at 51.2x FY16F earnings
- Maintain HOLD, TP revised to RM6.33/ S$2.09
HOLD, TP: RM6.33.
- We maintain our HOLD recommendation for IHH with a revised TP of RM6.33/ S$2.09.
- While we like its geographical diversification and premium healthcare services provider status, we believe current valuation at c.51.2x FY16F PE reflects this.
4Q15 strong due to exceptional items; FY15 core in line.
- IHH’s 4Q15 reported net profit surged 74% y-o-y to RM415.8m on revenues of RM2.3bn (+18%). This was due exceptional items (EI) of RM201.2m.
- Excluding EI, 4Q15 core net profit would have been RM214.6m, down 11% y-o-y, due to higher finance costs and depreciation expenses of new hospitals.
- FY15 core profits were in line, growing by 15% y-o-y to RM899m on revenues of RM8.46bn (+15%) arising from organic growth and contribution from new hospitals.
- While inpatient admissions numbers were fairly lacklustre, revenue growth was helped by higher revenue intensities and more complex cases handled.
Growth to continue but a tad slower pace.
- We project growth to continue but a tad slower in FY16F. We trimmed our earnings forecast by 8% to factor in slower growth in admissions, higher costs, pre-operating expenses and interest expenses.
- Valuations continue to remain lofty at 51.2x FY16F PE, reflecting its long-term growth profile and premium status.
Valuation:
- Our target price is revised to RM6.33 (S$2.09), rolling our valuations forward to FY17F/18F.
- We continue to adopt the sum-of-parts valuation methodology to reflect IHH's various operations and growth profiles across the different geographies.
Key Risks to Our View:
- Economic slowdown. While healthcare is deemed as a defensive sector, private healthcare will, nonetheless, be impacted by a slowdown in the economy, since elective procedures can be deferred and patients may choose public hospitals as a lower-cost alternative.
Andy Sim
DBS Vickers
|
http://www.dbsvickers.com/
2016-02-26
DBS Vickers
SGX Stock
Analyst Report
2.09
Up
2.04